Day One Biopharmaceuticals News and Activities
Presence
Day One Biopharmaceuticals develops and commercializes targeted cancer medicines. Its products and services focus on pediatric and adult oncology treatments for patients, hospitals, and oncology specialists.
Day One Biopharmaceuticals products and services overview:
- Cancer medicines
- Targeted therapies
- Pediatric oncology
- Adult oncology
- Drug development
Revenue: ~$120 million
Employees: 260
Headquarters: Brisbane, United States (USA)
Laboratoire Servier has 6 subsidiaries including Biogaran, Day One Biopharmaceuticals and Servier Laboratory and Industrial.
They are in:
- Pharmaceuticals71%
- Biotechnology29%
Acquisition, funding and merger involving Laboratoire Servier.
- Laboratoire Servier has acquired Day One Biopharmaceuticals (posted on April 24 2026).
- Laboratoire Servier has announced the acquisition of Day One Biopharmaceuticals (posted on March 9 2026).
- Day One Biopharmaceuticals has announced the acquisition of Mersana Therapeutics (posted on November 13 2025).
Executives
View the org chart displaying its 25 main executives
Most searched biographies at Day One Biopharmaceuticals
- Jeremy Bender, Chief Executive Officer and Director
- Garry Nicholson, Chairman of the Board
- Scott Garland, Director
Popular executive movements at Day One Biopharmaceuticals
- Saira Ramasastry, Director, has left the company (posted on April 27 2026).
- Habib Dable, Director, has left the company (posted on April 27 2026).
Popular executive movements at Laboratoire Servier
- Eric Fohlen-Weill, Director of External Communication, has left the company (posted on October 17 2025).
Create your alert
to follow the executive moves at Day One Biopharmaceuticals.
Biotechnology
Laboratoire Servier has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Day One Biopharmaceuticals
- Day One Reports Third Quarter 2023 Financial Results and Corporate Progress | Day One Biopharmaceuticals, Inc.
- Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) | Day One Biopharmaceuticals, Inc.
- Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) | Day One Biopharmaceuticals, Inc.
- Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience | Day One Biopharmaceuticals, Inc.
- Day One Reports Second Quarter 2023 Financial Results and Corporate Progress | Day One Biopharmaceuticals, Inc.
- About – DayOne
- View more press releases Close
Social media about Day One Biopharmaceuticals
- Day One Biopharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Day One Biopharmaceuticals on LinkedIn, X (Twitter) & YouTube
